The following mechanisms have been implicated in the same: activation of JNK in osteosarcoma [118], inactivation of AKT in osteosarcoma and colorectal cancer [115,118], inactivation of the PKA–PLK1 pathway in colorectal cancer [118], and inactivation of the IKKβ–ΝF-κB pathway in prostate cancer [121], and upregulation of DR5 through ROS-mediated induction of CHOP in colorectal cancer [114]. Here, DDIT3 is linked to osteosarcoma.